NT5E and non-small cell lung carcinoma: With regards to NSCLC, the activity of monalizumab was recently explored in the COAST trial (NCT03822351), an open-label phase II, randomized study in which patients who had been treated with chemo-radiation for inoperable stage III NSCLC were randomized to receive maintenance with durvalumab alone, the current standard of care, or durvalumab in combination with either oleclumab (an anti-CD73 agent) or monalizumab.